局部晚期胰腺癌放化疗中的剂量提升研究
该回顾性研究纳入2005至2015年497例接受新辅助或根治性放化疗的局部晚期胰腺癌患者,按总剂量分为<61Gy组(345例)和≥61Gy组(152例)。结果显示≥61Gy组在1年OS、PFS、LFFR和DFFR上均显著更高,多因素分析后≥61Gy仍是OS、PFS、LFFR和DFFR的显著有利因素;倾向评分匹配后≥61Gy组OS、PFS和LFFR仍更高,但DFFR无显著差异(p=0.205)。两组急性和晚期毒性无显著差异。
要点
- ≥61Gy组1年OS、PFS、LFFR和DFFR均显著高于<61Gy组。
- 多因素分析显示总剂量≥61Gy是OS、PFS、LFFR和DFFR的显著有利因素。
- 倾向评分匹配后≥61Gy组OS、PFS和LFFR仍更高,但DFFR无显著差异。
核心结论
- 接受更高放疗剂量的局部晚期胰腺癌患者不仅PFS和LFFR改善,OS也改善,且未增加严重毒性。
- 剂量提升的放化疗可作为局部晚期胰腺癌患者的有利治疗选择。
研究设计与样本
- 回顾性研究,纳入2005至2015年497例接受新辅助或根治性放化疗的局部晚期胰腺癌患者。
- 按总剂量分为<61Gy组(n=345)和≥61Gy组(n=152),并进行倾向评分匹配。
主要发现
- 中位随访19.3个月(范围4.8-128.5个月),≥61Gy组1年OS、PFS、LFFR和DFFR显著更高。
- 多因素分析显示总剂量≥61Gy是OS(p=0.019)、PFS(p=0.001)、LFFR(p=0.004)和DFFR(p=0.008)的显著有利因素。
- 倾向评分匹配后,≥61Gy组OS、PFS和LFFR仍更高,但DFFR无显著差异(p=0.205)。
- 两组急性和晚期毒性发生率无显著差异。
关键数值与推荐
- 总剂量≥61Gy为剂量提升组,<61Gy为对照组。
- 多因素分析中总剂量≥61Gy对OS的p=0.019,对PFS的p=0.001,对LFFR的p=0.004,对DFFR的p=0.008。
- 倾向评分匹配后DFFR比较的p=0.205。
临床怎么用
- 对局部晚期胰腺癌患者,可考虑将放化疗总剂量提升至≥61Gy以改善生存和局部控制。
- 剂量提升未增加严重毒性,但需结合患者具体情况个体化决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate whether radiotherapy (RT) dose escalation would improve treatment outcomes without increasing severe toxicity in locally advanced pancreatic cancer patients. METHODS: From 2005 to 2015, 497 locally advanced pancreatic cancer patients who received neoadjuvant or definitive chemoradiotherapy (CCRT) were included. Patients were divided according to the total dose (TD). Overall survival (OS), progression-free survival (PFS), local failure-free rate (LFFR), distant failure-free rate (DFFR), and toxicity rates were compared between <61Gy (n=345) and ≥61Gy groups (n=152). Additionally, propensity score matching was performed. RESULTS: At a median follow-up of 19.3months (range, 4.8-128.5months), the 1-year OS, PFS, LFFR, and DFFR were significantly higher in the ≥61Gy group. After multivariate analysis, a TD of ≥61Gy remained a significant favorable factor for OS (p=0.019), PFS (p=0.001), LFFR (p=0.004), and DFFR (p=0.008). After propensity score matching, the ≥61Gy group still showed higher OS, PFS, and LFFR, but not DFFR (p=0.205). The acute and late toxicity rates showed no significant difference between the two groups. CONCLUSION: Patients who received a higher RT dose showed not only improved PFS and LFFR, but also improved OS without an increase in severe toxicity. Dose-escalated CCRT can be a favorable treatment option in locally advanced pancreatic cancer patients.
引用
- Chung SY, Chang JS, Lee BM, et al. Dose escalation in locally advanced pancreatic cancer patients receiving chemoradiotherapy. Radiother Oncol. 2017. PMID: 28464997. doi:10.1016/j.radonc.2017.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。